Tivic Health: Christina Valauri Appointed to Board of Directors
Tivic Health: Christina Valauri Appointed to Board of Directors
Wall Street Capital Markets Veteran and Recognized All-Star Bio-Medical Technology Analyst joins Tivic Health's Governance Team
資本市場老兵和受認可的全明星生物醫學技術分析師加入Tivic Health的治理團隊
SAN FRANCISCO – June 18, 2024 – Tivic Health Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024.
舊金山-2024年6月18日– Tivic Health Systems，Inc.("Tivic Health"，納斯達克：TIVC)是一家健康科技公司，致力於開發和商業化生物電醫學，欣然歡迎Christina Valauri於2024年7月1日加入其董事會。
Ms. Valauri has served as a strategic advisor to the company since April 2023, and brings over 30-years of experience as a seasoned capital markets professional with extensive analytical and management experience. Ms. Valauri has a proven track record as a senior healthcare analyst, US and Global Head of Equity Research, senior broker-dealer manager, strategic business consultant, and board director and advisor. As a managing director and senior manager within capital markets, she has successfully developed and executed transformational business strategies in the US and internationally to drive growth, and provide enhanced operating performance and comprehensive regulatory and supervisory oversight. She has held leadership roles at US and international firms, including as the Global Director of Research at Cantor Fitzgerald, and senior research management roles at Credit Lyonnais, ING and Natixis.
Valauri女士自2023年4月以來一直擔任該公司的戰略顧問，並帶來了30多年的資本市場專業人士經驗，具有廣泛的分析和管理經驗。Valauri女士是資深的醫療保健分析師，美國和全球權益研究主管，高級經紀人經理，戰略業務顧問，董事和顧問。作爲資本市場內的董事和高級管理人員，她成功地在美國和國際市場上開發和執行了改革性的業務策略，以推動增長，並提供增強的運營績效和全面的監管和監督。她曾在國際公司擔任領導職務，包括作爲康泰菲舞格菲的全球研究總監，以及在克里迪里昂、荷蘭國際集團和法國外貿銀行擔任高級研究管理職務。
Ms. Valauri's career in equity securities research expands the Tivic boards' deep expertise in pharmaceutical, biotech, and med-tech industries. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations, as well as mentoring and advising C-suite teams of private and public early-stage healthcare companies through product development, regulatory, go-to-market strategies, potential mergers and acquisitions, and IPOs.
Valauri女士在股票研究方面的職業生涯擴展了Tivic董事會在製藥、生物科技和醫療技術行業的深厚專業知識。她擁有廣泛的經驗，能夠識別和分析突破性創新的商業潛力，並指導和建議私營和上市初創醫療保健公司的C級團隊進行產品開發、監管、營銷策略、潛在的併購和IPO。
Ms. Valauri currently serves as an Entrepreneur in Residence at Weill Cornell Medicine BioVenture eLab, where she applies her skills and experience in life sciences and business. She supports and facilitates the organization's mission to foster an entrepreneurial ecosystem related to the innovations of researchers and clinicians. Ms. Valauri is the founder and CEO of Sagestone Advisory, LLC., and also serves as a senior advisor with Hanover International, Inc. and Astia.org. She has been recognized by The Wall Street Journal's "Best on The Street" All-Star Analyst Survey and has received the Award for Excellence in Medical Education Public Affairs - Association of American Medical Colleges. Ms. Valauri earned her BA in Biology from Reed College and an MBA from Cornell University.
Valauri女士目前擔任威爾康奈爾醫學生物風險企業實驗室的企業家居住者，她將她在生命科學和商業方面的技能和經驗應用於該組織的使命，以培育與研究人員和臨床醫生創新相關的創業生態系統。Valauri女士是Sagestone Advisory, LLC的創始人兼首席執行官，也是Hanover International, Inc和Astia.org的高級顧問。她曾被《華爾街日報》“街頭最佳”全明星分析師調查評選認可，並獲得醫學教育公共事務協會的卓越獎。Valauri女士獲得了Reed College的生物學學士學位和康奈爾大學的工商管理碩士學位。
"Over the past year, as an advisor to our Board and the company, Christina Valauri has demonstrated deep commitment to excellence and the highest standards of ethical governance. This, paired with her insight into capital markets and deep background in research analysis, is a powerful combination to help ensure we make the best decisions for the company, our customers and our shareholders," stated Sheryle Bolton, Chair of the Board.
“在過去的一年裏，作爲我們董事會和公司的顧問，Christina Valauri表現出了深厚的卓越承諾和最高水平的道德治理標準。加上她對資本市場的洞察力和深厚的研究分析背景，這是一個有力的組合，可以幫助確保我們爲公司、客戶和股東做出最好的決策，”Sheryle Bolton，董事會主席表示。
"I could not be more excited that Christina has agreed to serve on our board of directors, particularly as we forge new segments in our bioelectronic portfolio, focused on precision modulation of vagus nerve activity," shared Jennifer Ernst, Chief Executive Officer of Tivic Health.
“我非常興奮Christina已經同意加入我們的董事會，尤其是在我們開闢了新的生物電子組合領域，聚焦迷走神經活動的精準調節，”Tivic Health首席執行官Jennifer Ernst分享。
Additionally, independent director, Karen Drexler, tendered her resignation from the board and the committees thereof, effective September 30, after which she will be continuing with the company as a strategic advisor. Ms. Drexler previously served as an advisor to the company from August 2017 through August 2019 when she joined Tivic Health's board as the company's first independent director. Ernst continued, "Karen was an instrumental force in the early formation of Tivic Health. I deeply appreciate her commitment to Tivic Health's development for the past eight years and her continued support as a strategic advisor to the company."
此外，獨立董事Karen Drexler於2024年9月30日前提出了辭職並退出董事會及其委員會，隨後她將繼續擔任該公司的戰略顧問。Drexler女士曾於2017年8月至2019年8月擔任該公司的顧問，然後加入Tivic Health董事會成爲公司的第一位獨立董事。恩斯特繼續說道，“在Tivic Health早期的發展中，Karen是一個重要的推動力。我非常感激她在過去八年中對Tivic Health的發展作出的貢獻，並在繼續擔任公司戰略顧問方面給予我們的支持。”
About Tivic Health
關於Tivic Health
Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health's patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic Health's non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health's first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth
Tivic Health是一家商業健康科技公司，正在推動生物電醫學領域的發展。Tivic Health的專利技術平台利用三叉、交感和迷走神經結構的刺激。Tivic Health通過針對性和非侵入性的方式，治療慢性炎症性健康問題，爲消費者和供應商提供高安全性、低風險和廣泛應用的無藥物治療解決方案。 Tivic Health的第一個商業產品ClearUP是一款經FDA認證的便攜式生物電鼻竇設備，已獲得專業醫生的推薦，並可通過在線零售商和商業分銷商購買 。有關更多信息，請訪問http://tivichealth.com @TivicHealth
Forward-Looking Statements
前瞻性聲明
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: statements regarding the expansion of Tivic Health's product portfolio; changes in board composition; Ms. Drexler's service as an advisor to the company; market and other conditions; macroeconomic factors, including inflation; and unexpected costs, charges or expenses that reduce Tivic Health's capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic Health's actual results to differ from those contained in the forward-looking statements, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading "Risk Factors"; as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
本新聞稿可能包含“前瞻性聲明”，其面臨重大風險和不確定性。本新聞稿中包含的所有聲明，除非是歷史事實的陳述，都屬於前瞻性聲明。本新聞稿中包含的前瞻性聲明可能會使用“預期”、“相信”、“思考”、“可能”、“估計”、“期待”、“打算”、“尋求”、“可能”、“計劃”、“潛力”、“預測”、“項目”、“目標”、“瞄準”、“應該”、“將”、“願望”或這些詞的否定形式或其他類似的表達方式，但並非所有前瞻性聲明都包含這些詞。 Tivic Health Systems，Inc.的前瞻性聲明基於其目前的預期，並受到難以預測的固有不確定性、風險和假設的影響。此外，某些前瞻性聲明基於未來事件的假設，這些事件可能不會被證明是準確的。 由於各種因素，實際結果可能會與任何前瞻性聲明所包含的結果有很大不同，這些因素包括以“擴展Tivic Health的產品組合”爲例的語句，董事會構成的變化，Drexler女士作爲公司顧問的服務，市場和其他情況，宏觀經濟因素，包括通貨膨脹，以及意外的成本、費用或支出，這些成本、費用或支出可能會減少Tivic Health的資本資源。鑑於這些風險和不確定性，您應該謹慎地評估這些前瞻性聲明。對於其他風險和不確定性以及其他重要因素的討論，其中任何一個可能導致Tivic Health的實際結果與前瞻性聲明所包含的結果不同，請參見Tivic Health向美國證監會提交的文件，包括其於2024年3月29日提交的年度報告10-K的“風險因素”一節，以及該公司隨後向美國證監會提交的文件。本新聞稿中包含的前瞻性聲明截至本日，Tivic Health Systems，Inc.除了適用的法律規定外，不承擔更新此類信息的責任。
Media Contact:
媒體聯繫人：
Morgan Luke
Morgan Luke
Investor Contact:
投資者聯繫人：
Hanover International, Inc.
Hanover International, Inc.
譯文內容由第三人軟體翻譯。